- Conformis Inc CFMS announced results of a published retrospective study of procedures using Conformis' patient-specific iTotal CR (cruciate-retaining) knee replacement implant.
- Data showed that implant survivorship was 98.5% with 8 revisions (representing 1.5% of the 540 implants reviewed) at a mean follow-up of 2.8 years.
- 89% of the patients reported being either satisfied or highly satisfied.
- The researchers reviewed patient records and conducted patient report outcome surveys of 540 knees in 433 patients who underwent personalized total knee arthroplasty.
- Related Link: Investors React To Conformis' Annual Sales Guidance Update.
- Price Action: CFMS stock is up 1.55% at $1.31 during the premarket session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
